<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01868438</url>
  </required_header>
  <id_info>
    <org_study_id>SP-C-017-12</org_study_id>
    <nct_id>NCT01868438</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability of Pyronaridine-artesunate in Tablet and Granule Formulations, in Healthy Volunteers</brief_title>
  <official_title>Phase 1, Open-label, Cross-over Study to Investigate the Relative Bioavailability of Pyramax (Pyronaridine-artesunate) in Tablet and Granule Formulations, in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shin Poong Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicines for Malaria Venture</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the bioavailability of two formulations (tablets and
      granules for dispersion) of the antimalarial drug Pyramax (which is a combination of
      pyronaridine and artesunate).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the concentration-time Curve from hour 0 to the last sampling point (AUC 0-t) for pyronaridine and dihydroartemisinin (DHA)</measure>
    <time_frame>Pyronaridine PK to Day 43; DHA PK to 24 hours post dose.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Pyronaridine-artesunate granules (Period 1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In first dosing period, single administration of pyronaridine-artesunate granules: total dose 540mg pyronaridine + 180mg artesunate.
In second dosing period, cross-over to single administration of pyronaridine-artesunate tablets: total dose 540mg pyronaridine + 180mg artesunate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pyronaridine-artesunate tablets (Period1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In first dosing period, single administration of pyronaridine-artesunate tablets: total dose 540mg pyronaridine + 180mg artesunate.
In second dosing period, cross-over to single administration of pyronaridine-artesunate granules: total dose 540mg pyronaridine + 180mg artesunate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pyronaridine-artesunate granules</intervention_name>
    <arm_group_label>Pyronaridine-artesunate granules (Period 1)</arm_group_label>
    <arm_group_label>Pyronaridine-artesunate tablets (Period1)</arm_group_label>
    <other_name>Pyramax granules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyronaridine-artesunate tablets</intervention_name>
    <arm_group_label>Pyronaridine-artesunate granules (Period 1)</arm_group_label>
    <arm_group_label>Pyronaridine-artesunate tablets (Period1)</arm_group_label>
    <other_name>Pyramax tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects between the ages of 20 and 45 years, inclusive.
             (Healthy is defined as no clinically relevant abnormalities identified by a detailed
             medical history, full physical examination, including blood pressure and pulse rate
             measurement, 12-lead ECG and clinical laboratory tests)

          -  Weight between 50 kg and 80 kg and Body Mass Index (BMI) calculated using Quetelet's
             Index - weight(kg)/height (m2) between 18.5 to 27 kg/m2;

          -  An informed consent document signed and dated by the subject (prior to screening and
             any study activities, including discontinuation of any prohibited medications)

          -  Strictly normal values of alanine aminotransferase(ALT), aspartate aminotransferase
             (AST), and bilirubin, and normal or abnormal but clinically insignificant results of
             the other blood and urine laboratory parameters at screening.

          -  Female subjects of non-childbearing potential [i.e., physiologically incapable of
             becoming pregnant, including any female who was post-menopausal (i.e., one year
             without menses) or who has undergone sterilization (via hysterectomy or bilateral
             tubal ligation)]

          -  Female subjects of childbearing potential with a negative urine pregnancy test at
             screening, and a negative pregnancy blood test on admission, and who :

               -  agree to double barrier method of contraception for 4 weeks before first study
                  drug administration and throughout the entire study follow up period, or

               -  whose partner has undergone vasectomy and has been negative for sperm for at
                  least 6 months

          -  Subjects who are willing and able to comply with scheduled visits, treatment plan,
             laboratory tests, and other study procedures.

        Exclusion Criteria:

          -  Known history or evidence of clinically significant disorders such as cardiovascular
             (including arrhythmia, acute corrected QT interval (QTc) greater or equal to 450
             milliseconds), respiratory (including active tuberculosis), hepatic, renal,
             gastrointestinal, immunological (including active HIV-AIDS), neurological (including
             auditory), endocrine, infectious, malignancy, psychiatric or other abnormality
             (including head trauma)

          -  Known history of hypersensitivity, allergic or adverse reactions to pyronaridine or
             artesunate or other artemisinins

          -  Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen (HBsAg) or
             Hepatitis C antibody (HCV Ab)

          -  Seropositive HIV antibody, seropositive syphilis [Syphilis reagin test (+)]

          -  Previous exposure to pyronaridine-artesunate (Pyramax)

          -  Present or recent history (last two years) of tobacco abuse (â‰¥10 cigarettes/day)

          -  Known or suspected alcohol abuse or illicit drug use up to 5 years before the study
             start or positive findings on urine drug screen

          -  Intake of alcoholic beverages or caffeine-containing food or beverages, such as
             coffee, tea, chocolate, or cola, 48 hours before study drug administration

          -  Intake of grapefruit, Seville oranges or products containing these from 72 hours
             before the start of study drug administration

          -  Gilbert's disease

          -  Use of over-the-counter (OTC) medications, including vitamins, analgesics,
             antipyretics or antacids within 7 days before study drug administration

          -  Use of prescription medications within 14 days before the start of study drug
             administration or required chronic use of any prescription medication

          -  Use of enzyme-altering agents (e.g. barbiturates, phenothiazines, cimetidine, etc.)
             within 30 days before the start of study drug administration

          -  Plasma donation within 60 days before the start of study drug administration

          -  Blood donation of 500 mL or more within 60 days before the start of study drug
             administration

          -  Participation AND having had drug administration in any other clinical study within
             the 60 days before start of study drug administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dept. of Clinical Pharmacology and Therapeutics, Asan Medical Center, Univ. of Ulsan</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2013</study_first_submitted>
  <study_first_submitted_qc>May 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2013</study_first_posted>
  <last_update_submitted>March 28, 2014</last_update_submitted>
  <last_update_submitted_qc>March 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pyronaridine artesunate tablet</keyword>
  <keyword>Pyronaridine artesunate granules</keyword>
  <keyword>Pyramax tablet</keyword>
  <keyword>Pyramax granules</keyword>
  <keyword>Bioavailability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Pyronaridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

